## Kirin Holdings (2503.T) — EDINET deep dive (FY2024 + key events through Jan 2026) ### Executive takeaway Kirin is a **pure holding company** overseeing a large portfolio (177 consolidated subsidiaries; 28 equity-method affiliates) spanning **Alcoholic Beverages, Soft Drinks, Pharmaceuticals, and Health Sciences**. ["177 consolidated subsidiaries"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["28 equity method affiliates"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) In FY2024 (year ended **Dec 31, 2024**), **revenue grew** but **reported profit fell sharply**, driven by (i) **step-acquisition loss** related to FANCL becoming a consolidated subsidiary and (ii) losses/costs tied to Kyowa Hakko Bio’s amino acid/HMO business transfer preparations, alongside an **impairment on equity-method investments**. ["Sales revenue…2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Profit attributable…58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Loss on step acquisition…18,265"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["provision for loss on transfer…16,597"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Impairment loss on equity method investments…19,255"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 1) Business model & portfolio logic (what Kirin is trying to build) ### Segment structure (and why it matters) Kirin’s current reportable segments are **Alcoholic Beverages, Soft Drinks, Pharmaceuticals, and Health Science**. ["four reportable segments"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) This segmentation was explicitly tied to the long-term vision **KV2027**, with Health Science positioned as the “third pillar” alongside Food & Beverage and Pharma. ["Kirin Group Vision 2027\" (KV2027)"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["make the health sciences sector its third pillar"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ### KV2027: targets & capital philosophy Kirin frames success around **EPS growth** and **ROIC exceeding cost of capital**, with specific targets and a definition for ROIC disclosed in EDINET. ["aim to increase shareholder value through growth in EPS"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["ROIC = Earnings before interest and taxes /"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) **Financial targets (management plan):** | Target (per Kirin disclosure) | 2025 target | 2027 target | Long-term goal | |---|---:|---:|---:| | ROIC | 7.2% ["2025 target…7.2%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 9.0% ["2027 target…9.0%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 10%+ ["10% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | EPS | ¥185 ["EPS…185 yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | “3-year CAGR + high single digit% (6%+)” ["3-year CAGR…(6% or more)"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | “CAGR + high single-digit %” ["CAGR + high single-digit percentage"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Dividend policy shift:** Kirin states it will move from “≥40% payout of normalized EPS” to **progressive dividends** with **DOE ≥ 5%** as a target (from FY2025 onward). ["change its dividend policy…progressive dividends"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["targeting a DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 2) FY2024 financial performance (IFRS, continuing operations) — what actually happened ### 2.1 Consolidated P&L (FY2024 vs FY2023) **JPY millions (¥m)** | Metric | FY2023 | FY2024 | Δ | Notes | |---|---:|---:|---:|---| | Revenue | 2,134,393 ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 2,338,385 ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | +203,992 (computed) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Topline growth was solid. | | Gross profit | 963,466 ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 1,065,955 ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | +102,489 (computed) ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | — | | Operating profit | 150,294 ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 125,340 ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -24,954 (computed) ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Operating profit fell despite revenue growth. | | Profit before tax | 197,049 ["197,049"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 139,721 ["139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -57,328 (computed) ["197,049"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Sharp decline pre-tax. | | Net income (total) | 150,438 ["150,438"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 85,811 ["85,811"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -64,627 (computed) ["150,438"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["85,811"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | — | | Net income attributable to owners | 112,697 ["112,697"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 58,214 ["58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -54,483 (computed) ["112,697"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Large drop to owners. | **Margin snapshot (computed):** | Margin | FY2023 | FY2024 | |---|---:|---:| | Gross margin | 45.1% (computed) ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 45.6% (computed) ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Operating margin | 7.0% (computed) ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 5.4% (computed) ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Analyst interpretation (filing-grounded):** the income statement shows **lower operating profit** and **much lower pre-tax profit**, while the notes show material “below/other” items such as **loss on step acquisitions (¥18,265m)** and **impairment loss on equity method investments (¥19,255m)**—both consistent with why earnings to owners compressed. ["Operating profit…125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Pre-tax profit…139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Loss on step acquisitions…18,265"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Impairment loss on equity method investments…19,255"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ### 2.2 Segment mix: where growth came from (and what did/didn’t translate into profit) **Kirin’s FY2024 vs FY2023 segment results (JPY billions):** | Segment | Revenue FY2024 | Revenue FY2023 | Business profit FY2024 | Business profit FY2023 | |---|---:|---:|---:|---:| | Alcoholic Beverages | ¥1,817.0 ["Alcoholic beverages…1.817 trillion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥1,451.0 ["1.451 trillion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥124.0 ["Alcoholic beverages…124"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥119.9 ["119.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Soft Drinks | ¥564.9 ["beverage…564.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥516.2 ["516.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥64.0 ["beverage…64"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥52.4 ["52.4"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Pharmaceuticals | ¥495.3 ["Pharmaceuticals…495.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥441.9 ["441.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥91.9 ["Pharmaceuticals…91.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥96.0 ["96"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Health Science | ¥175.3 ["Health Sciences…175.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥103.4 ["103.4"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥10.9 ["Health Sciences…-10.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥12.5 ["-12.5"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Other | ¥21.3 ["others…21.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥27.8 ["27.8"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥58.0 ["others…-58"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥54.2 ["-54.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **What this implies:** FY2024 growth was broad-based with outsized revenue growth in **Health Science** (+69.6% per Kirin’s table), but **Health Science remained loss-making at the “business profit” level** in FY2024, meaning the portfolio shift is still in the “investment/transition” phase rather than already margin accretive. ["Health Sciences…69.6%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Health Sciences…-10.9 billion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 3) Balance sheet & capital structure (FY2024 year-end) ### 3.1 Selected balance-sheet items (Dec 31, 2024 vs Dec 31, 2023; JPY millions) | Line item | Dec 31, 2023 | Dec 31, 2024 | |---|---:|---:| | Total assets | 2,869,585 ["Total Assets…2,869,585"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 3,354,159 ["Total Assets…3,354,159"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Goodwill | 390,568 ["Noren…390,568"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 501,480 ["501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Intangible assets | 303,540 ["Intangible assets…303,540"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 659,561 ["659,561"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Equity ratio (owners of parent) | 39.5% ["Ratio of equity…39.5"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 35.2% ["35.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Read-through:** Asset growth is heavily skewed to **goodwill and intangibles**, consistent with Kirin’s recent portfolio moves (e.g., FANCL consolidation, other Health Science/Pharma actions disclosed in the filing’s corporate history timeline). ["Noren…501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Intangible assets…659,561"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["FANCL Corporation becomes a consolidated subsidiary"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 4) Cash flow & capital allocation (FY2024) ### 4.1 Consolidated cash flow statement (JPY millions) | Cash flow | FY2023 | FY2024 | |---|---:|---:| | Operating cash flow | 203,206 ["Cash flows from operating activities…203,206"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 242,844 ["242,844"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Investing cash flow | -226,091 ["Cash flows from investing activities…△ 226,091"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -329,375 ["△ 329,375"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Financing cash flow | 35,909 ["Cash flows from financing activities…35,909"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 58,125 ["58,125"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Cash & equivalents (end of period) | 131,399 ["Cash…and…131,399"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 118,617 ["118,617"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ### 4.2 What changed in FY2024 * **Operating cash flow improved** to ¥242.8bn, but **investing outflows widened** to ¥329.4bn, consistent with a year of heavy portfolio/capex activity. ["Cash flows from operating activities…242,844"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Cash flows from investing activities…△ 329,375"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) * Kirin explicitly ties shareholder returns to (historic) **≥40% payout on normalized EPS**, then pivots toward **progressive dividends / DOE ≥5%**, which signals an intent to reduce volatility in payouts while managing debt and growth investment. ["payout ratio of at least 40% on normalized EPS"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["progressive dividends…DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 5) Interim performance: H1 2025 (Jan 1–Jun 30, 2025) — momentum & portfolio impacts ### 5.1 H1 2025 vs H1 2024 headline results (JPY billions unless noted) | Metric | H1 2024 | H1 2025 | |---|---:|---:| | Revenue | 1,095.823 ["Sales revenue…1,095,823"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 1,136.309 ["1,136,309"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Business profit | 93.069 ["Segment profit…93,069"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 94.245 ["94,245"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Operating profit | 80.890 ["Operating profit…80,890"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 68.723 ["68,723"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Profit attributable to owners | 57.220 ["Owner…57,220"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 52.835 ["52,835"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | EPS (yen) | 70.65 ["Basic earnings…70.65"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 65.23 ["65.23"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | **Management explanation (H1 2025):** revenue rose mainly due to FANCL’s contribution, but the Alcoholic Beverages business revenue declined (price revision-related volume decline + FX), and profit to owners fell due to losses in other operating and financial items despite higher business profit. ["overall revenue increased due to the contribution of FANCL"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["decreased in the alcohol beverages business"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["decreased due to a loss in both other operating"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ### 5.2 H1 2025 segment results (external revenue, JPY billions) | Segment | H1 2024 | H1 2025 | |---|---:|---:| | Alcoholic Beverages | 512.499 ["Alcoholic…512,499"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 492.628 ["492,628"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Soft Drinks | 270.044 ["beverage…270,044"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 271.805 ["271,805"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Pharmaceuticals | 232.842 ["232,842"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 230.498 ["230,498"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Health Science | 69.564 ["Health…69,564"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 127.247 ["127,247"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | --- ## 6) Event / extraordinary filings: what changed recently (and why investors care) ### 6.1 Kyowa Hakko Bio amino acid & HMO business transfer (Health Science) Kirin discloses that Kyowa Hakko Bio entered into an agreement (Nov 22, 2024) to transfer its amino acid and HMO business, with procedures **completed July 1, 2025**, and transfer proceeds (¥16,872m) recorded in interim cash flows. ["entered into an agreement"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["completed on July 1, 2025"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["transfer price was 16,872 million yen"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) This matters because it links directly to FY2024 “other operating expenses” where Kirin recorded **one-time expenses / provision for loss on transfer** (including ¥16,597m) associated with the agreement. ["16,597 million yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ### 6.2 FANCL ownership increased to 100% (post-consolidation cleanup) During H1 2025, Kirin’s ownership in FANCL increased **from 75.62% to 100%**, with an **acquisition price of ¥82,573m** (cash, incl. accounts payable), booked as “payments for acquisition of subsidiaries’ interests from non-controlling interests.” ["ownership interest…75.62% to 100%"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["acquisition price was ¥82,573 million"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ### 6.3 Jan 2026 Extraordinary Report: liquidation of a specified subsidiary (Lion Global Craft Beverages Pty Ltd) On **Jan 6, 2026**, Kirin filed an extraordinary report stating it decided to **dissolve and liquidate** **Lion Global Craft Beverages Pty Ltd** (Australia), meaning it will no longer be a “specified subsidiary.” ["Submission date…January 6, 2026"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["dissolve and liquidate"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["Lion Global Craft Beverages Pty Ltd"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["During 2026 (liquidation scheduled to be completed)"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) --- ## 7) Key questions I would focus on next (based on filings) 1) **Can Health Science turn profitable at the “business profit” level** after portfolio cleanup (e.g., Kyowa Hakko Bio transfer) and full FANCL ownership? ["Health Sciences…-10.9 billion yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["completed on July 1, 2025"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) 2) **Is ROIC recovery plausible** from the FY2024 low (Kirin cites ROIC 4.1% for FY2024 results) while balance sheet intangibles/goodwill expanded? ["ROIC was 4.1%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Noren…501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) 3) How will the new **progressive dividend / DOE ≥5%** policy interact with debt and ongoing investment needs? ["progressive dividends"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- If you want, I can extend this into a **model-like pack** (still EDINET-only): (i) bridge from **segment business profit → consolidated operating profit** (using “other operating income/expenses” lines), and (ii) a **timeline table** linking FY2024 earnings impacts to the specific disclosed events (FANCL consolidation, Kyowa Hakko Bio transfer, equity-method impairment).

## Kirin Holdings (2503.T) — EDINET deep dive (FY2024 + key events through Jan 2026) ### Executive takeaway Kirin is a **pure holding company** overseeing a large portfolio (177 consolidated subsidiaries; 28 equity-method affiliates) spanning **Alcoholic Beverages, Soft Drinks, Pharmaceuticals, and Health Sciences**. ["177 consolidated subsidiaries"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["28 equity method affiliates"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) In FY2024 (year ended **Dec 31, 2024**), **revenue grew** but **reported profit fell sharply**, driven by (i) **step-acquisition loss** related to FANCL becoming a consolidated subsidiary and (ii) losses/costs tied to Kyowa Hakko Bio’s amino acid/HMO business transfer preparations, alongside an **impairment on equity-method investments**. ["Sales revenue…2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Profit attributable…58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Loss on step acquisition…18,265"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["provision for loss on transfer…16,597"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Impairment loss on equity method investments…19,255"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 1) Business model & portfolio logic (what Kirin is trying to build) ### Segment structure (and why it matters) Kirin’s current reportable segments are **Alcoholic Beverages, Soft Drinks, Pharmaceuticals, and Health Science**. ["four reportable segments"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) This segmentation was explicitly tied to the long-term vision **KV2027**, with Health Science positioned as the “third pillar” alongside Food & Beverage and Pharma. ["Kirin Group Vision 2027\" (KV2027)"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["make the health sciences sector its third pillar"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ### KV2027: targets & capital philosophy Kirin frames success around **EPS growth** and **ROIC exceeding cost of capital**, with specific targets and a definition for ROIC disclosed in EDINET. ["aim to increase shareholder value through growth in EPS"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["ROIC = Earnings before interest and taxes /"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) **Financial targets (management plan):** | Target (per Kirin disclosure) | 2025 target | 2027 target | Long-term goal | |---|---:|---:|---:| | ROIC | 7.2% ["2025 target…7.2%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 9.0% ["2027 target…9.0%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 10%+ ["10% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | EPS | ¥185 ["EPS…185 yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | “3-year CAGR + high single digit% (6%+)” ["3-year CAGR…(6% or more)"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | “CAGR + high single-digit %” ["CAGR + high single-digit percentage"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Dividend policy shift:** Kirin states it will move from “≥40% payout of normalized EPS” to **progressive dividends** with **DOE ≥ 5%** as a target (from FY2025 onward). ["change its dividend policy…progressive dividends"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["targeting a DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 2) FY2024 financial performance (IFRS, continuing operations) — what actually happened ### 2.1 Consolidated P&L (FY2024 vs FY2023) **JPY millions (¥m)** | Metric | FY2023 | FY2024 | Δ | Notes | |---|---:|---:|---:|---| | Revenue | 2,134,393 ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 2,338,385 ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | +203,992 (computed) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Topline growth was solid. | | Gross profit | 963,466 ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 1,065,955 ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | +102,489 (computed) ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | — | | Operating profit | 150,294 ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 125,340 ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -24,954 (computed) ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Operating profit fell despite revenue growth. | | Profit before tax | 197,049 ["197,049"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 139,721 ["139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -57,328 (computed) ["197,049"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Sharp decline pre-tax. | | Net income (total) | 150,438 ["150,438"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 85,811 ["85,811"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -64,627 (computed) ["150,438"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["85,811"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | — | | Net income attributable to owners | 112,697 ["112,697"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 58,214 ["58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -54,483 (computed) ["112,697"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["58,214"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | Large drop to owners. | **Margin snapshot (computed):** | Margin | FY2023 | FY2024 | |---|---:|---:| | Gross margin | 45.1% (computed) ["963,466"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 45.6% (computed) ["1,065,955"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Operating margin | 7.0% (computed) ["150,294"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,134,393"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 5.4% (computed) ["125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["2,338,385"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Analyst interpretation (filing-grounded):** the income statement shows **lower operating profit** and **much lower pre-tax profit**, while the notes show material “below/other” items such as **loss on step acquisitions (¥18,265m)** and **impairment loss on equity method investments (¥19,255m)**—both consistent with why earnings to owners compressed. ["Operating profit…125,340"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Pre-tax profit…139,721"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Loss on step acquisitions…18,265"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Impairment loss on equity method investments…19,255"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ### 2.2 Segment mix: where growth came from (and what did/didn’t translate into profit) **Kirin’s FY2024 vs FY2023 segment results (JPY billions):** | Segment | Revenue FY2024 | Revenue FY2023 | Business profit FY2024 | Business profit FY2023 | |---|---:|---:|---:|---:| | Alcoholic Beverages | ¥1,817.0 ["Alcoholic beverages…1.817 trillion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥1,451.0 ["1.451 trillion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥124.0 ["Alcoholic beverages…124"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥119.9 ["119.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Soft Drinks | ¥564.9 ["beverage…564.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥516.2 ["516.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥64.0 ["beverage…64"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥52.4 ["52.4"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Pharmaceuticals | ¥495.3 ["Pharmaceuticals…495.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥441.9 ["441.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥91.9 ["Pharmaceuticals…91.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥96.0 ["96"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Health Science | ¥175.3 ["Health Sciences…175.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥103.4 ["103.4"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥10.9 ["Health Sciences…-10.9"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥12.5 ["-12.5"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Other | ¥21.3 ["others…21.3"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ¥27.8 ["27.8"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥58.0 ["others…-58"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -¥54.2 ["-54.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **What this implies:** FY2024 growth was broad-based with outsized revenue growth in **Health Science** (+69.6% per Kirin’s table), but **Health Science remained loss-making at the “business profit” level** in FY2024, meaning the portfolio shift is still in the “investment/transition” phase rather than already margin accretive. ["Health Sciences…69.6%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Health Sciences…-10.9 billion"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 3) Balance sheet & capital structure (FY2024 year-end) ### 3.1 Selected balance-sheet items (Dec 31, 2024 vs Dec 31, 2023; JPY millions) | Line item | Dec 31, 2023 | Dec 31, 2024 | |---|---:|---:| | Total assets | 2,869,585 ["Total Assets…2,869,585"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 3,354,159 ["Total Assets…3,354,159"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Goodwill | 390,568 ["Noren…390,568"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 501,480 ["501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Intangible assets | 303,540 ["Intangible assets…303,540"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 659,561 ["659,561"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Equity ratio (owners of parent) | 39.5% ["Ratio of equity…39.5"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 35.2% ["35.2"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | **Read-through:** Asset growth is heavily skewed to **goodwill and intangibles**, consistent with Kirin’s recent portfolio moves (e.g., FANCL consolidation, other Health Science/Pharma actions disclosed in the filing’s corporate history timeline). ["Noren…501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Intangible assets…659,561"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["FANCL Corporation becomes a consolidated subsidiary"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 4) Cash flow & capital allocation (FY2024) ### 4.1 Consolidated cash flow statement (JPY millions) | Cash flow | FY2023 | FY2024 | |---|---:|---:| | Operating cash flow | 203,206 ["Cash flows from operating activities…203,206"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 242,844 ["242,844"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Investing cash flow | -226,091 ["Cash flows from investing activities…△ 226,091"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | -329,375 ["△ 329,375"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Financing cash flow | 35,909 ["Cash flows from financing activities…35,909"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 58,125 ["58,125"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | | Cash & equivalents (end of period) | 131,399 ["Cash…and…131,399"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | 118,617 ["118,617"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) | ### 4.2 What changed in FY2024 * **Operating cash flow improved** to ¥242.8bn, but **investing outflows widened** to ¥329.4bn, consistent with a year of heavy portfolio/capex activity. ["Cash flows from operating activities…242,844"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Cash flows from investing activities…△ 329,375"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) * Kirin explicitly ties shareholder returns to (historic) **≥40% payout on normalized EPS**, then pivots toward **progressive dividends / DOE ≥5%**, which signals an intent to reduce volatility in payouts while managing debt and growth investment. ["payout ratio of at least 40% on normalized EPS"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["progressive dividends…DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- ## 5) Interim performance: H1 2025 (Jan 1–Jun 30, 2025) — momentum & portfolio impacts ### 5.1 H1 2025 vs H1 2024 headline results (JPY billions unless noted) | Metric | H1 2024 | H1 2025 | |---|---:|---:| | Revenue | 1,095.823 ["Sales revenue…1,095,823"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 1,136.309 ["1,136,309"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Business profit | 93.069 ["Segment profit…93,069"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 94.245 ["94,245"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Operating profit | 80.890 ["Operating profit…80,890"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 68.723 ["68,723"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Profit attributable to owners | 57.220 ["Owner…57,220"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 52.835 ["52,835"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | EPS (yen) | 70.65 ["Basic earnings…70.65"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 65.23 ["65.23"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | **Management explanation (H1 2025):** revenue rose mainly due to FANCL’s contribution, but the Alcoholic Beverages business revenue declined (price revision-related volume decline + FX), and profit to owners fell due to losses in other operating and financial items despite higher business profit. ["overall revenue increased due to the contribution of FANCL"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["decreased in the alcohol beverages business"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["decreased due to a loss in both other operating"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ### 5.2 H1 2025 segment results (external revenue, JPY billions) | Segment | H1 2024 | H1 2025 | |---|---:|---:| | Alcoholic Beverages | 512.499 ["Alcoholic…512,499"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 492.628 ["492,628"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Soft Drinks | 270.044 ["beverage…270,044"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 271.805 ["271,805"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Pharmaceuticals | 232.842 ["232,842"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 230.498 ["230,498"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | | Health Science | 69.564 ["Health…69,564"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | 127.247 ["127,247"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) | --- ## 6) Event / extraordinary filings: what changed recently (and why investors care) ### 6.1 Kyowa Hakko Bio amino acid & HMO business transfer (Health Science) Kirin discloses that Kyowa Hakko Bio entered into an agreement (Nov 22, 2024) to transfer its amino acid and HMO business, with procedures **completed July 1, 2025**, and transfer proceeds (¥16,872m) recorded in interim cash flows. ["entered into an agreement"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["completed on July 1, 2025"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["transfer price was 16,872 million yen"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) This matters because it links directly to FY2024 “other operating expenses” where Kirin recorded **one-time expenses / provision for loss on transfer** (including ¥16,597m) associated with the agreement. ["16,597 million yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ### 6.2 FANCL ownership increased to 100% (post-consolidation cleanup) During H1 2025, Kirin’s ownership in FANCL increased **from 75.62% to 100%**, with an **acquisition price of ¥82,573m** (cash, incl. accounts payable), booked as “payments for acquisition of subsidiaries’ interests from non-controlling interests.” ["ownership interest…75.62% to 100%"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ["acquisition price was ¥82,573 million"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) ### 6.3 Jan 2026 Extraordinary Report: liquidation of a specified subsidiary (Lion Global Craft Beverages Pty Ltd) On **Jan 6, 2026**, Kirin filed an extraordinary report stating it decided to **dissolve and liquidate** **Lion Global Craft Beverages Pty Ltd** (Australia), meaning it will no longer be a “specified subsidiary.” ["Submission date…January 6, 2026"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["dissolve and liquidate"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["Lion Global Craft Beverages Pty Ltd"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) ["During 2026 (liquidation scheduled to be completed)"](12267bc8-1948-4069-95e1-9c218eb0bba1:139:original.html) --- ## 7) Key questions I would focus on next (based on filings) 1) **Can Health Science turn profitable at the “business profit” level** after portfolio cleanup (e.g., Kyowa Hakko Bio transfer) and full FANCL ownership? ["Health Sciences…-10.9 billion yen"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["completed on July 1, 2025"](42c65ee5-c25c-4e0c-b838-8c18bc5a766e:517:original.html) 2) **Is ROIC recovery plausible** from the FY2024 low (Kirin cites ROIC 4.1% for FY2024 results) while balance sheet intangibles/goodwill expanded? ["ROIC was 4.1%"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["Noren…501,480"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) 3) How will the new **progressive dividend / DOE ≥5%** policy interact with debt and ongoing investment needs? ["progressive dividends"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) ["DOE…5% or more"](57a07376-b7f7-4671-b95b-3cd32dcdcdd8:555:original.html) --- If you want, I can extend this into a **model-like pack** (still EDINET-only): (i) bridge from **segment business profit → consolidated operating profit** (using “other operating income/expenses” lines), and (ii) a **timeline table** linking FY2024 earnings impacts to the specific disclosed events (FANCL consolidation, Kyowa Hakko Bio transfer, equity-method impairment).